Pruritus News and Research

RSS
AMAG fourth quarter total revenues decrease to $14.9 million

AMAG fourth quarter total revenues decrease to $14.9 million

NEJM publishes results from two Jakafi Phase III studies on MF

NEJM publishes results from two Jakafi Phase III studies on MF

Valeant receives FDA approval for secondary supplier of Methoxsalen

Valeant receives FDA approval for secondary supplier of Methoxsalen

Genzyme announces four-year data from eliglustat tartrate phase 2 trial on Gaucher disease type 1

Genzyme announces four-year data from eliglustat tartrate phase 2 trial on Gaucher disease type 1

Mylan acquires two dermatological drugs from Valeant

Mylan acquires two dermatological drugs from Valeant

AMAG completes enrollment in Feraheme Phase III program for iron-deficiency anemia

AMAG completes enrollment in Feraheme Phase III program for iron-deficiency anemia

LEO Pharma receives FDA approval for Picato topical gel to treat AK

LEO Pharma receives FDA approval for Picato topical gel to treat AK

Baxter to commence second GAMMAGARD LIQUID Phase III trial in Alzheimer's

Baxter to commence second GAMMAGARD LIQUID Phase III trial in Alzheimer's

Baxter submits GAMMAGARD LIQUID sBLA to FDA for treatment of MMN

Baxter submits GAMMAGARD LIQUID sBLA to FDA for treatment of MMN

Oxygen Biotherapeutics to commence study to determine efficacy of Dermacyte in relieving Histamine induced pruritus

Oxygen Biotherapeutics to commence study to determine efficacy of Dermacyte in relieving Histamine induced pruritus

Baxter receives FDA approval for ADVATE to prevent hemophilia A

Baxter receives FDA approval for ADVATE to prevent hemophilia A

Positive results from Hatchtech's DeOvo Phase 2b trial on head lice

Positive results from Hatchtech's DeOvo Phase 2b trial on head lice

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

S*BIO announces results from pacritinib Phase 2 study on myelofibrosis

S*BIO announces results from pacritinib Phase 2 study on myelofibrosis

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene announces interim results of REVLIMID study on CLL

Celgene announces interim results of REVLIMID study on CLL

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Consistent data from three studies support plans for rindopepimut with ACT IV Phase 3 study

Consistent data from three studies support plans for rindopepimut with ACT IV Phase 3 study